Financial News for Vertex Pharmaceuticals, Incorporated (VRTX)
| VRTX | 3/12/2010 8:10PM | 52 Week Price Range | Market Capitalization | Dividend Yield | Recent Dividend |
|---|---|---|---|---|---|
| $43.46 | $25.94 — $44.24 | $8.7 Billion | n/a | n/a |
Want to Sharpen Your Investing?
Learn how Ockham can help investors make informed decisions and slice through the noise. Learn more about Ockham's services.
Explore Why Ockham?
Analysts' opinions can often carry a lot of weight, especially when they make major news and are covered on The Call.
When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Vertex Pharmaceuticals, Incorporated has actually sunk a bit in comparison to the others. As of this week's report, we have an Overvalued valuation on VRTX because the price has gotten too high to be justified by the fundamentals. Our sentiment indicator, provided through the Motley Fool CAPS survey, suggests that investors are neutral overall towards VRTX and think that it will generally perform in-line with the S&P 500.
- Vertex Pharmaceuticals, Incorporated VRTX has increased in price by 3.52% since it was mentioned on The Call.
- Melissa Francis mentioned quite a few stocks, 16 individual companies to be exact. You can see the all company slices for The Call on the recap page.
- There were 2 mentions of VRTX on just this episode. You can see the all company slices of those on the The Call recap page.
- VRTX has had 1 mentions, on various business television shows, since this one. Find out what was said with the latest financial news on Vertex Pharmaceuticals, Incorporated.